A pre-planned interim analysis of OS after a minimum follow-up of 3 years showed a trend in favor of ERd versus Rd (median OS: ERd, 43.7 months; Rd, 39.6 months; HR, 0.77; 95% CI, 0.61–0.97), although OS curves at that time were not fully mature, limiting full interpretation 16 .
← all excerpts
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
1
—
—